Table 1.

mTOR inhibitors clinically studied in malignancies

mTOR inhibitor	Mechanism of action	FDA-approved indications in clinical practice (www.fda.gov)
Sirolimus	Allosteric mTOR inhibitor	Renal transplant Drug-eluting stents for coronary artery disease
Everolimus	Allosteric mTOR inhibitor	Renal transplant Advanced Neuroendocrine tumors of pancreatic origin Advanced hormone receptor-positive HER2-negative breast cancer Advanced renal cell carcinoma Renal angiomyolipoma and subependymal giant cell astrocytoma associated with tuberous sclerosis complex
Temsirolimus	Allosteric mTOR inhibitor	Advanced Renal cell carcinoma